The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
-
ORGANIZATION Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
-
BUSINESS Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
-
REGULATORY Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
-
REGULATORY Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
-
BUSINESS 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
-
REGULATORY Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
-
BUSINESS Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
-
BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
-
BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
-
BUSINESS Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
-
REGULATORY MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
-
BUSINESS Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
-
BUSINESS Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
-
BUSINESS Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
-
BUSINESS Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
-
BUSINESS AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
-
BUSINESS DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
-
ORGANIZATION Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
-
REGULATORY MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…